Scarica l'app Stockscreener
1.13
1.74%
-0.02
Dopo l'orario di chiusura:
1.17
0.04
+3.54%
Precedente Chiudi:
$1.15
Aprire:
$1.16
Volume 24 ore:
1.67M
Relative Volume:
0.76
Capitalizzazione di mercato:
$258.04M
Reddito:
$8.95M
Utile/perdita netta:
$-21.49M
Rapporto P/E:
-9.4167
EPS:
-0.12
Flusso di cassa netto:
$-29.24M
1 W Prestazione:
+17.60%
1M Prestazione:
+5.61%
6M Prestazione:
+77.67%
1 anno Prestazione:
+8.65%
Intervallo 1D:
$1.12
$1.21
Intervallo di 1 settimana:
$0.9296
$1.21
Portata 52W:
$0.3651
$1.21
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Nome
Lineage Cell Therapeutics Inc
Settore
Industria
Telefono
510-871-4188
Indirizzo
2173 Salk Avenue, Suite 200, Carlsbad, CA
Confronta LCTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.13 | 262.61M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-20 | Iniziato | Craig Hallum | Buy |
| 2022-11-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-14 | Iniziato | B. Riley Securities | Buy |
| 2021-08-19 | Iniziato | Noble Capital Markets | Outperform |
| 2021-03-31 | Iniziato | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Borsa (LCTX) Ultime notizie
Is Lineage Cell Therapeutics Inc. a good long term investmentFree Smart Trading Workshop - PrintWeekIndia
Lineage Cell Therapeutics Inc. Stock Analysis and ForecastTremendous growth opportunities - PrintWeekIndia
What analysts say about Lineage Cell Therapeutics Inc. stockPhenomenal investment performance - PrintWeekIndia
What drives Lineage Cell Therapeutics Inc. stock priceFree Consultation - Autocar Professional
Stem Cell Therapy Market Attracts Investment in Neuro, Onco & - openPR.com
Why Lineage Cell Therapeutics Inc. stock attracts strong analyst attentionHigh Return Conservative Stocks - Newser
What makes Lineage Cell Therapeutics Inc. stock price move sharplyFree Stock Market Practical Discussion Forums - Newser
How Lineage Cell Therapeutics Inc. stock performs during market volatilityBreakout Momentum Stocks - Newser
Spinal Cord Injury Pipeline 2025: MOA And ROA Insights, Clinical Trials Status, And Key Companies Involved By Delveinsight Stemcyte, Nervgen Pharma, VA Office Of Research And Development, Kessler - MenaFN
Cell Therapy Manufacturing Market Exclusive Report with - openPR.com
Cell Therapy Manufacturing Market In-depth Insights, Business - openPR.com
Lineage Cell Therapeutics shareholders approve board slate and equity plan amendment - Investing.com
Lineage Cell stock holds steady as Roche presents positive 3-year data - Investing.com UK
Lineage Cell Therapeutics (LCTX) Drops 1.65% Amid OpRegen Trial Hype - AInvest
Two Sigma Investments LP Buys New Shares in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Rising Demand in Allogeneic Stem Cells Market USD 2.0Bn By 2031 - openPR.com
Squarepoint Ops LLC Takes $46,000 Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Cell Therapy Manufacturing Market Exclusive Report with Detailed Study Analysis | WuXi AppTec, Healios Ltd. - newstrail.com
Lineage Cell Therapeutics appoints new auditor - Investing.com Australia
Two Sigma Advisers LP Has $44,000 Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Jane Street Group LLC Buys 142,965 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium - BioSpace
Deutsche Bank AG Has $87,000 Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Future of Personalized Treatment: Stem Cell Therapy Market - openPR.com
Lineage Cell Therapeutics Inc Azioni (LCTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):